Alopecia in Children Following Living Related Liver Transplantation

Transplant Proc. 2021 Jan-Feb;53(1):228-232. doi: 10.1016/j.transproceed.2020.05.020. Epub 2020 Jun 27.

Abstract

Introduction: Alopecia is a common complication in patients following kidney transplantation; however, reports regarding liver transplantation patients are still few.

Methods: This study followed 111 children who underwent living related liver transplantation. Alopecia patients and its possible risk factors were analyzed.

Results: Alopecia occurred in 3 patients (2.7%). Underlying diseases were biliary atresia and Alagille syndrome. Clinically significant alopecia (universal alopecia) occurred in 1 patient with Alagille syndrome. All patients received tacrolimus as their immunosuppression drug. None of the patients who received cyclosporine experienced alopecia. The onset of alopecia ranged from 7 to 28 months after transplantation. Alopecia was treated with a topical corticosteroid and topical tacrolimus, but 1 patient with clinically severe alopecia required conversion from tacrolimus to cyclosporine A.

Conclusions: Alopecia is 1 complication seen in children receiving tacrolimus therapy following living donor liver transplant. Prompt management of this cosmetic complication should be done to ensure patients' compliance to medication regimen.

MeSH terms

  • Alopecia / epidemiology
  • Alopecia / immunology*
  • Child, Preschool
  • Cyclosporine / therapeutic use
  • Female
  • Humans
  • Immunocompromised Host*
  • Immunosuppression Therapy / adverse effects
  • Immunosuppressive Agents / adverse effects*
  • Infant
  • Liver Transplantation* / adverse effects
  • Living Donors
  • Male
  • Tacrolimus / adverse effects*

Substances

  • Immunosuppressive Agents
  • Cyclosporine
  • Tacrolimus